Literature DB >> 7670536

Serum levels of tumor necrosis factor in patients with American cutaneous leishmaniasis.

M Castes1, D Trujillo, M E Rojas, C T Fernandez, L Araya, M Cabrera, J Blackwell, J Convit.   

Abstract

The purpose of this study was to evaluate serum levels of TNF-alpha in patients with either of the three clinical forms of American cutaneous leishmaniasis. The 86 patients examined were classified as having either the localized (LCL: 22 patients), mucocutaneous (MCL: 45 patients), or the rare diffuse (DCL: 19 patients) form of the disease. Our results show a significant increase in the mean level of TNF-alpha in the three groups of patients when compared to controls. MCL patients produce significantly higher levels of TNF-alpha than DCL patients. The proportion of individuals positive for serum TNF-alpha was significantly higher in both MCL and DCL patients than in the controls. No significant differences were found in the level of TNF-alpha when compared between before and after cure of 12 patients with MCL. There were no significant correlations between the level of TNF-alpha and the skin test diameter. The results will be discussed in terms of the pathogenesis of the disease in its different clinical forms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7670536

Source DB:  PubMed          Journal:  Biol Res        ISSN: 0716-9760            Impact factor:   5.612


  20 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  FLI1 polymorphism affects susceptibility to cutaneous leishmaniasis in Brazil.

Authors:  L Castellucci; S E Jamieson; E N Miller; L F de Almeida; J Oliveira; A Magalhães; L H Guimarães; M Lessa; E Lago; A R de Jesus; E M Carvalho; J M Blackwell
Journal:  Genes Immun       Date:  2011-06-02       Impact factor: 2.676

Review 3.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

4.  CD4(+) T cells defined by their Vβ T cell receptor expression are associated with immunoregulatory profiles and lesion size in human leishmaniasis.

Authors:  T S L Keesen; L R V Antonelli; D R Faria; L H Guimarães; O Bacellar; E M Carvalho; W O Dutra; K J Gollob
Journal:  Clin Exp Immunol       Date:  2011-07-04       Impact factor: 4.330

5.  Lesion size correlates with Leishmania antigen-stimulated TNF-levels in human cutaneous leishmaniasis.

Authors:  Fabiano Oliveira; Andre Bafica; Andrea B Rosato; Cecilia B F Favali; Jackson M Costa; Virginia Cafe; Manoel Barral-Netto; Aldina Barral
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

6.  Up-regulation of Th1-type responses in mucosal leishmaniasis patients.

Authors:  Olívia Bacellar; Hélio Lessa; Albert Schriefer; Paulo Machado; Amélia Ribeiro de Jesus; Walderez O Dutra; Kenneth J Gollob; Edgar M Carvalho
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

7.  Wound healing genes and susceptibility to cutaneous leishmaniasis in Brazil.

Authors:  Léa Castellucci; Sarra E Jamieson; Lucas Almeida; Joyce Oliveira; Luiz Henrique Guimarães; Marcus Lessa; Michaela Fakiola; Amélia Ribeiro de Jesus; E Nancy Miller; Edgar M Carvalho; Jenefer M Blackwell
Journal:  Infect Genet Evol       Date:  2012-03-28       Impact factor: 3.342

8.  Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.

Authors:  Anne Maurer-Cecchini; Saskia Decuypere; François Chappuis; Coralie Alexandrenne; Simonne De Doncker; Marleen Boelaert; Jean-Claude Dujardin; Louis Loutan; Jean-Michel Dayer; Gianfranco Tulliano; Jorge Arevalo; Alexandro Llanos-Cuentas; Carlo Chizzolini
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

9.  Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-alpha production.

Authors:  Anselmo S Souza; Angela Giudice; Júlia Mb Pereira; Luís H Guimarães; Amelia R de Jesus; Tatiana R de Moura; Mary E Wilson; Edgar M Carvalho; Roque P Almeida
Journal:  BMC Infect Dis       Date:  2010-07-15       Impact factor: 3.090

10.  CXCR1 and SLC11A1 polymorphisms affect susceptibility to cutaneous leishmaniasis in Brazil: a case-control and family-based study.

Authors:  Léa Castellucci; Sarra E Jamieson; E Nancy Miller; Eliane Menezes; Joyce Oliveira; Andrea Magalhães; Luiz Henrique Guimarães; Marcus Lessa; Amélia Ribeiro de Jesus; Edgar M Carvalho; Jenefer M Blackwell
Journal:  BMC Med Genet       Date:  2010-01-20       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.